Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS

Key Points

• Cwm LLC trimmed its stake in Apellis by 55.6% in Q4, selling 52,353 shares and retaining 41,880 shares worth about $1.05 million per its latest 13F filing.
• Institutional ownership is very high at 96.29%; notable moves include SG Americas boosting its position by 35.9% to 567,046 shares (≈$14.24M) while several other funds also added exposure.
• Analysts have a consensus rating of “Hold” with an average price target of $34.89; the stock trades near a one‑year high (~$40.95) after reporting an EPS beat despite year‑over‑year revenue weakness.

Cwm LLC trimmed its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 55.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,880 shares of the company's stock after selling 52,353 shares during the period. Cwm LLC's holdings in Apellis Pharmaceuticals were worth $1,052,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. grew its holdings in Apellis Pharmaceuticals by 7.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 51,933 shares of the company's stock valued at $1,305,000 after purchasing an additional 3,804 shares during the period. SG Americas Securities LLC grew its holdings in Apellis Pharmaceuticals by 35.9% during the fourth quarter. SG Americas Securities LLC now owns 567,046 shares of the company's stock valued at $14,244,000 after purchasing an additional 149,654 shares during the period. Diversified Trust Co. bought a new position in Apellis Pharmaceuticals during the fourth quarter valued at $476,000. Wedmont Private Capital grew its holdings in Apellis Pharmaceuticals by 4.1% during the fourth quarter. Wedmont Private Capital now owns 11,883 shares of the company's stock valued at $315,000 after purchasing an additional 468 shares during the period. Finally, Allworth Financial LP grew its holdings in Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock valued at $50,000 after purchasing an additional 857 shares during the period. 96.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Apellis Pharmaceuticals in a report on Monday, December 29th. Mizuho raised their price target on Apellis Pharmaceuticals from $20.00 to $41.00 and gave the stock a "neutral" rating in a report on Thursday, April 2nd. Royal Bank Of Canada cut their price target on Apellis Pharmaceuticals from $22.00 to $21.00 and set a "sector perform" rating for the company in a report on Wednesday, February 25th. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $19.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Finally, Jefferies Financial Group lowered Apellis Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $34.89.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $40.95 on Tuesday. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $40.96. The business has a fifty day moving average price of $28.09 and a 200-day moving average price of $24.89. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. The firm has a market capitalization of $5.23 billion, a P/E ratio of 315.02 and a beta of -0.19.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.86. The company had revenue of $199.91 million during the quarter, compared to analyst estimates of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The firm's quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. As a group, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.23 EPS for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.